Meta-analyses have revealed a wide variance in cumulative ovarian cancer risk for BRCA mutation carriers, on average 40% in BRCA1 versus 11-18% in BRCA2 mutation carriers [1,2]. This evidence concerns the gene BRCA2 and ovarian carcinoma.